Your Article Summary
See Latest ArticlesBiologics dont need long market exclusivity, FTC says
American Medical News , 06/30/09
Trapp D - A recent Federal Trade Commission report asserting that original biopharmaceutical drug manufacturers do not need lengthy exclusive marketing periods to maintain innovation has not driven supporters from a bill that would extend such protection.
Related Articles
Nabi Biopharmaceuticals to Hold Conference Call
Nabi Biopharmaceuticals, 11/17/09
Relevance Score: 87%
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Bristol Myers-Squibb Company, 11/11/09
Relevance Score: 84%
Nabi Biopharmaceuticals Participates in NicVAX(R) Phase IIb Study
Nabi Biopharmaceuticals, 10/29/09
Relevance Score: 84%
Nabi Biopharmaceuticals to Announce Third Quarter Financial Results on November 2009
Nabi Biopharmaceuticals, 10/28/09
Relevance Score: 84%
Sanofi-aventis to acquire FOVEA, a French biopharmaceutical ophthalmology company
Sanofi-aventis, 10/02/09
Relevance Score: 84%
Today in Law/Ethics/Regulations...keeping you current
Receive free subspecialty "5-minute updates" via email
Subject positions in research ethics committee letters: a discursive analysis
Clinical Ethics, 12/01/09
An ethical justification for the Chronic Care Model (CCM)
Health Expectations, 12/01/09
Solo doctors and ethical isolation
Journal of Medical Ethics, 11/30/09